ProQR Therapeutics (PRQR) Competitors $2.06 -0.01 (-0.24%) As of 02:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR vs. ZYME, AKBA, MLYS, TRVI, LENZ, NRIX, URGN, NUVB, SION, and SNDXShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Zymeworks (ZYME), Akebia Therapeutics (AKBA), Mineralys Therapeutics (MLYS), Trevi Therapeutics (TRVI), LENZ Therapeutics (LENZ), Nurix Therapeutics (NRIX), Urogen Pharma (URGN), Nuvation Bio (NUVB), Sionna Therapeutics (SION), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Its Competitors Zymeworks Akebia Therapeutics Mineralys Therapeutics Trevi Therapeutics LENZ Therapeutics Nurix Therapeutics Urogen Pharma Nuvation Bio Sionna Therapeutics Syndax Pharmaceuticals Zymeworks (NYSE:ZYME) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations. Do analysts rate ZYME or PRQR? Zymeworks currently has a consensus target price of $21.00, indicating a potential upside of 69.70%. ProQR Therapeutics has a consensus target price of $8.00, indicating a potential upside of 287.41%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media refer more to ZYME or PRQR? In the previous week, Zymeworks and Zymeworks both had 2 articles in the media. ProQR Therapeutics' average media sentiment score of 0.89 beat Zymeworks' score of 0.29 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in ZYME or PRQR? 92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings & valuation, ZYME or PRQR? ProQR Therapeutics has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$93.38M9.23-$118.67M-$1.49-8.31ProQR Therapeutics$20.46M10.62-$30.04M-$0.35-5.90 Which has more risk & volatility, ZYME or PRQR? Zymeworks has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Is ZYME or PRQR more profitable? ProQR Therapeutics has a net margin of -157.04% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% ProQR Therapeutics -157.04%-53.49%-22.07% SummaryProQR Therapeutics beats Zymeworks on 9 of the 14 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$217.05M$3.02B$5.54B$9.49BDividend YieldN/A2.46%4.73%4.14%P/E Ratio-5.8917.8129.0424.35Price / Sales10.62181.11374.0878.76Price / CashN/A40.5624.4827.20Price / Book2.278.908.645.82Net Income-$30.04M-$54.98M$3.24B$264.73M7 Day Performance-5.71%1.97%0.22%-0.99%1 Month Performance-3.64%17.07%7.96%6.06%1 Year Performance8.68%14.52%29.96%23.79% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics1.9996 of 5 stars$2.07-0.2%$8.00+287.4%+16.3%$217.05M$20.46M-5.89180Positive NewsZYMEZymeworks3.0592 of 5 stars$13.46+1.0%$21.00+56.0%+23.5%$937.93M$93.38M-8.97460Upcoming EarningsAKBAAkebia Therapeutics3.8047 of 5 stars$3.59+0.8%$6.75+88.0%+200.8%$934.98M$160.18M-17.09430Upcoming EarningsMLYSMineralys Therapeutics2.5655 of 5 stars$13.60-5.0%$32.25+137.1%+10.1%$933.31MN/A-3.6528News CoverageUpcoming EarningsTRVITrevi Therapeutics2.991 of 5 stars$7.64-2.9%$20.88+173.2%+160.5%$923.10MN/A-16.9820Upcoming EarningsLENZLENZ Therapeutics1.694 of 5 stars$31.51-0.3%$48.60+54.2%+22.1%$889.98MN/A-17.80110Earnings ReportAnalyst RevisionGap UpNRIXNurix Therapeutics2.5089 of 5 stars$11.93+3.6%$29.31+145.7%-45.7%$880.69M$88.38M-4.57300URGNUrogen Pharma4.6197 of 5 stars$18.90-0.3%$32.86+73.8%+26.8%$875.52M$90.40M-5.94200Upcoming EarningsAnalyst ForecastNUVBNuvation Bio2.0246 of 5 stars$2.55+2.0%$7.17+181.0%-31.3%$850.66M$7.87M-1.0960Upcoming EarningsSIONSionna TherapeuticsN/A$19.85+3.9%$38.50+94.0%N/A$842.78MN/A0.0035Lockup ExpirationGap UpSNDXSyndax Pharmaceuticals3.6913 of 5 stars$9.57-0.6%$34.10+256.3%-50.7%$828.64M$23.68M-2.48110News CoverageEarnings ReportAnalyst ForecastGap Up Related Companies and Tools Related Companies Zymeworks Competitors Akebia Therapeutics Competitors Mineralys Therapeutics Competitors Trevi Therapeutics Competitors LENZ Therapeutics Competitors Nurix Therapeutics Competitors Urogen Pharma Competitors Nuvation Bio Competitors Sionna Therapeutics Competitors Syndax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
